tiprankstipranks
Trending News
More News >
Chugai Pharmaceutical Co Ltd (JP:4519)
:4519
Advertisement

Chugai Pharmaceutical Co (4519) AI Stock Analysis

Compare
3 Followers

Top Page

JP:4519

Chugai Pharmaceutical Co

(OTC:4519)

Rating:72Outperform
Price Target:
¥7,186.00
▲(10.40% Upside)
Chugai Pharmaceutical Co's strong financial performance and positive earnings call sentiment are key strengths, contributing significantly to the overall score. However, technical indicators suggest a bearish trend, and the high P/E ratio indicates potential overvaluation, which slightly offsets the positive aspects.

Chugai Pharmaceutical Co (4519) vs. iShares MSCI Japan ETF (EWJ)

Chugai Pharmaceutical Co Business Overview & Revenue Model

Company DescriptionChugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
How the Company Makes MoneyChugai Pharmaceutical generates revenue primarily through the sales of its proprietary pharmaceutical products, particularly in oncology and other specialty therapeutic areas. A significant portion of its income comes from the commercialization of its innovative drugs, including those developed internally and through partnerships. The company has strategic collaborations with Roche, its largest shareholder, which allows for shared research and development costs, as well as access to international markets. Additionally, Chugai earns revenue through licensing agreements and royalties from its patented drug technologies. The company also invests in research to expand its pipeline of new therapies, further enhancing its future revenue potential.

Chugai Pharmaceutical Co Earnings Call Summary

Earnings Call Date:Jul 24, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 24, 2025
Earnings Call Sentiment Neutral
The earnings call presented a balanced view with significant revenue growth and successful R&D milestones on one hand, and challenges such as project discontinuation and potential future tariff impacts on the other.
Q2-2025 Updates
Positive Updates
Increased Revenue and Profit
Revenue increased by 4.6% to JPY 578.5 billion. Operating profit increased by 3.5%, and net income increased by 2.1% compared to the previous year.
Successful R&D Milestones
The global Phase III trial for orforglipron showed success, and new projects such as MINT91 and AUBE00 began Phase I trials.
Strong Sales Performance
Domestic sales increased by 2.8%, and overseas sales increased by 7.3%. Actemra exports were particularly strong.
New Investments
An investment of JPY 80 billion to build a new research building at the Ukima site, focusing on environmentally friendly equipment.
Negative Updates
Impact of NHI Drug Price Revisions
Domestic sales were negatively impacted by NHI drug price revisions and the penetration of generics.
Discontinuation of Projects
Five early-stage in-house projects were discontinued to focus resources on higher priority projects.
Challenges in Export and Tariff Concerns
Delays in Hemlibra exports and potential future impact from U.S. tariffs on pharmaceuticals.
Increased Cost of Sales
Cost of sales increased by 9.4%, with a rise in the cost-to-sales ratio due to higher composition costs for Actemra.
Company Guidance
During the call, the company provided detailed guidance and updates on its financial performance and strategic initiatives for the second quarter of fiscal year 2025. Revenue increased by 4.6% compared to the previous year, reaching JPY 578.5 billion, with operating profit up by 3.5% at JPY 272 billion. Net income also saw a rise of 2.1%. The growth was primarily driven by a 5.3% increase in sales, with domestic sales up by 2.8% and overseas sales up by 7.3%. However, domestic sales were negatively impacted by NHI drug price revisions and the penetration of generics, while new products like Phesgo and Vabysmo contributed positively. The company highlighted its R&D progress, including the successful Phase III trial of orforglipron and the initiation of new trials for projects like AUBE00. Additionally, a significant investment of JPY 80 billion was announced for a new research building to enhance manufacturing capabilities. The company also addressed the discontinuation of five early-stage projects to better focus resources on high-priority areas, aiming to achieve the goals set in their TOP I 2030 strategy.

Chugai Pharmaceutical Co Financial Statement Overview

Summary
Chugai Pharmaceutical Co exhibits strong financial health with robust profitability, low leverage, and effective cash flow management. While revenue growth has slowed, the company's strong margins and financial stability position it well for future growth opportunities.
Income Statement
85
Very Positive
Chugai Pharmaceutical Co shows strong profitability with a consistent gross profit margin around 71% in TTM, indicating efficient cost management. The net profit margin is robust at 33.56%, reflecting effective control over expenses. However, the revenue growth rate has declined by 2.12% in TTM, suggesting a need for growth strategies. EBIT and EBITDA margins are healthy, indicating strong operational performance.
Balance Sheet
88
Very Positive
The company maintains a very low debt-to-equity ratio of 0.0069 in TTM, highlighting financial stability and low leverage risk. Return on equity is strong at 22.29%, showcasing effective use of equity to generate profits. The equity ratio is solid, indicating a strong capital structure with a significant portion of assets financed by equity.
Cash Flow
82
Very Positive
Chugai Pharmaceutical Co demonstrates strong cash flow management with a 12.14% growth in free cash flow in TTM. The operating cash flow to net income ratio is nearly 2, indicating efficient conversion of net income into cash. The free cash flow to net income ratio is high at 85.43%, reflecting strong cash generation relative to profits.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.20T1.17T1.11T1.26T999.76B786.95B
Gross Profit841.80B830.75B693.01B783.06B660.27B511.77B
EBITDA558.97B574.80B475.64B562.66B450.30B328.72B
Net Income395.49B387.32B325.47B374.43B303.00B214.73B
Balance Sheet
Total Assets2.28T2.21T1.93T1.87T1.54T1.24T
Cash, Cash Equivalents and Short-Term Investments1.03T996.35B738.98B503.11B471.97B378.62B
Total Debt13.20B10.90B13.46B14.11B16.04B11.28B
Total Liabilities293.22B306.87B306.97B445.37B350.68B255.50B
Stockholders Equity1.99T1.90T1.63T1.42T1.19T980.00B
Cash Flow
Free Cash Flow397.33B396.68B335.67B172.87B206.76B143.62B
Operating Cash Flow464.10B447.60B409.93B244.11B279.63B205.03B
Investing Cash Flow-190.68B-227.37B-37.29B-145.99B-118.93B-98.31B
Financing Cash Flow-169.12B-141.01B-139.33B-145.64B-107.41B-99.50B

Chugai Pharmaceutical Co Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6509.00
Price Trends
50DMA
6911.44
Negative
100DMA
7174.93
Negative
200DMA
6963.81
Negative
Market Momentum
MACD
-189.85
Negative
RSI
47.11
Neutral
STOCH
79.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4519, the sentiment is Negative. The current price of 6509 is below the 20-day moving average (MA) of 6555.40, below the 50-day MA of 6911.44, and below the 200-day MA of 6963.81, indicating a bearish trend. The MACD of -189.85 indicates Negative momentum. The RSI at 47.11 is Neutral, neither overbought nor oversold. The STOCH value of 79.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4519.

Chugai Pharmaceutical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$10.70T27.0921.48%1.64%10.29%11.37%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
$19.81B35.115.46%4.52%
$44.67B22.3318.32%1.72%
$9.05B34.814.61%3.36%
$15.23B12.8013.71%4.52%
$47.59B45.091.99%4.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4519
Chugai Pharmaceutical Co
6,509.00
-256.69
-3.79%
ALPMF
Astellas Pharma
11.08
-0.61
-5.22%
DSKYF
Daiichi Sankyo Company
23.59
-17.74
-42.92%
KYKOF
Kyowa Kirin Co
17.13
-4.88
-22.17%
SGIOF
Shionogi & Co
18.01
3.23
21.85%
TKPHF
Takeda Pharmaceutical Co
27.45
-1.07
-3.75%

Chugai Pharmaceutical Co Corporate Events

Chugai Highlights Eli Lilly’s Positive Phase 3 Results for Orforglipron
Aug 7, 2025

Chugai Pharmaceutical Co., Ltd. announced Eli Lilly’s positive Phase 3 trial results for orforglipron, an oral GLP-1 receptor agonist, which showed significant weight reduction in adults with obesity. The trial demonstrated that orforglipron achieved primary and secondary endpoints, with a safety profile consistent with existing GLP-1 medicines. This development is significant for Eli Lilly’s market positioning in weight management solutions, though it does not impact Chugai’s financial forecast for 2025.

The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7650.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.

Chugai Pharmaceutical to Build New Laboratory to Boost R&D and Environmental Goals
Jul 24, 2025

Chugai Pharmaceutical Co. announced plans to construct a new laboratory building, UKX, at its Ukima Site in Tokyo to enhance its manufacturing process development capabilities and advance environmental initiatives. This strategic move is part of Chugai’s growth strategy, TOP I 2030, aiming to double R&D output and achieve early proof of concept in clinical development. The new facility will support rapid clinical trial entry and innovation in drug manufacturing processes, particularly for mid-size molecules. Additionally, the environmentally friendly design of UKX aligns with Chugai’s Mid-Term Environmental Goals 2030, focusing on reducing CO2 emissions and phasing out halogenated hydrocarbons. This investment is not expected to impact the company’s financial forecast for 2025.

The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7650.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.

Chugai Pharmaceutical Reports Strong H1 2025 Results and Announces Special Dividend
Jul 24, 2025

Chugai Pharmaceutical Co. reported a strong financial performance for the first half of 2025, with significant increases in revenue, operating profit, and net income compared to the previous year. The company announced a special dividend to celebrate its 100th anniversary, highlighting its robust financial health and commitment to rewarding shareholders. This announcement underscores Chugai’s solid market position and its strategic focus on sustainable growth, which is likely to have positive implications for its stakeholders.

The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7650.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.

Chugai Pharmaceutical’s Performance Highlighted in Roche’s Half-Year Results
Jul 24, 2025

Chugai Pharmaceutical Co., Ltd., a key player in the pharmaceutical industry, is significantly influenced by its parent company, Roche Holding Ltd, which owns a majority of its shares. The recent announcement of Roche’s half-year results for 2025 includes Chugai’s performance, highlighting the integrated financial outcomes and strategic alignment between the two companies. This announcement underscores the operational synergy and market positioning of Chugai within the Roche Group, potentially impacting stakeholders by showcasing the company’s performance and strategic direction.

The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7650.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025